{"id":"low-dose-rivaroxaban","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding (major and minor)"},{"rate":null,"effect":"Gastrointestinal bleeding"},{"rate":null,"effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rivaroxaban is a direct Factor Xa inhibitor that blocks a key enzyme in the intrinsic and extrinsic coagulation pathways. At low doses, it provides antiplatelet and anticoagulant effects suitable for thromboprophylaxis and cardiovascular event reduction without the bleeding risk of full-dose anticoagulation. This formulation is designed to balance efficacy in preventing thrombotic events with improved safety.","oneSentence":"Low-dose rivaroxaban selectively inhibits Factor Xa in the coagulation cascade, reducing thrombin generation and blood clot formation at a lower dose than standard anticoagulation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:53:29.942Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Thromboprophylaxis and cardiovascular event reduction in stable coronary artery disease or peripheral artery disease"},{"name":"Stroke prevention in atrial fibrillation (at reduced doses)"}]},"trialDetails":[{"nctId":"NCT03568890","phase":"PHASE4","title":"Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec","startDate":"2018-09-01","conditions":"Left Atrial Appendage Closure, Thrombosis, Stroke","enrollment":510},{"nctId":"NCT07497165","phase":"","title":"Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-11-01","conditions":"Relapsed/Refractory Multiple Myeloma (RRMM), Multiple Myeloma","enrollment":48},{"nctId":"NCT03969953","phase":"PHASE3","title":"Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease","status":"COMPLETED","sponsor":"The George Institute","startDate":"2021-01-18","conditions":"Chronic Kidney Diseases, Dialysis-dependent Kidney Failure, Cardiovascular Disease","enrollment":1753},{"nctId":"NCT05198960","phase":"PHASE3","title":"AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms","status":"RECRUITING","sponsor":"University Hospital, Brest","startDate":"2022-07-13","conditions":"Polycythemia Vera, Essential Thrombocythemia, Prefibrotic/Early Primary Myelofibrosis","enrollment":1308},{"nctId":"NCT07468448","phase":"PHASE3","title":"Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in IntraCranial Atherosclerotic diseaSe (CATIS- ICAS)","status":"NOT_YET_RECRUITING","sponsor":"Population Health Research Institute","startDate":"2026-05-30","conditions":"Ischemic Stroke, Intracranial Atherosclerosis","enrollment":1172},{"nctId":"NCT05047172","phase":"PHASE3","title":"Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2022-08-02","conditions":"Intracranial Arteriosclerosis, Stroke","enrollment":1683},{"nctId":"NCT07312851","phase":"PHASE1","title":"A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-01-19","conditions":"Healthy Participants","enrollment":186},{"nctId":"NCT04990791","phase":"PHASE4","title":"WILL lOWer Dose Aspirin be Better With Rivaroxaban in Patients With Chronic Coronary Syndromes?","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2021-08-26","conditions":"Coronary Syndrome","enrollment":48},{"nctId":"NCT06396858","phase":"PHASE4","title":"Anti-inflammatory and Anti-thrombotic Therapy With colcHicine and Low Dose Rivaroxaban for Major Adverse Cardiovascular Events Reduction in Ischemic Stroke","status":"NOT_YET_RECRUITING","sponsor":"Brazilian Clinical Research Institute","startDate":"2026-07","conditions":"Ischemic Stroke","enrollment":4500},{"nctId":"NCT07352358","phase":"PHASE4","title":"Randomized Trial of Anticoagulation Plus Batroxobin for Acute Cerebral Venous Thrombosis","status":"RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2026-01-30","conditions":"Cerebral Venous Thrombosis","enrollment":72},{"nctId":"NCT03968393","phase":"PHASE4","title":"Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress","status":"RECRUITING","sponsor":"Population Health Research Institute","startDate":"2019-06-14","conditions":"Stroke, Atrial Fibrillation","enrollment":2270},{"nctId":"NCT07316270","phase":"NA","title":"SAfety and eFfectiveness of cathetER Ablation for Atrial Fibrillation With Intracerebral Hemorrhage (SAFER-AF)","status":"NOT_YET_RECRUITING","sponsor":"Beijing Anzhen Hospital","startDate":"2026-01","conditions":"AF - Atrial Fibrillation, ICH - Intracerebral Hemorrhage","enrollment":646},{"nctId":"NCT07270263","phase":"NA","title":"Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies","status":"RECRUITING","sponsor":"Medical University of Gdansk","startDate":"2024-11-22","conditions":"Lymphoma, Leukemia, Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma","enrollment":100},{"nctId":"NCT06195540","phase":"PHASE3","title":"RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing","status":"RECRUITING","sponsor":"University Hospital, Angers","startDate":"2024-07-19","conditions":"Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism","enrollment":1424},{"nctId":"NCT07228663","phase":"PHASE3","title":"Hip Fracture Surgery Arterial and Venous Thrombotic Events Prevention","status":"NOT_YET_RECRUITING","sponsor":"McMaster University","startDate":"2025-12-01","conditions":"Hip Fracture Surgery, Cardiovascular Prevention, Venous Thromboembolism (VTE)","enrollment":100},{"nctId":"NCT04755283","phase":"PHASE2","title":"Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Anthos Therapeutics, Inc.","startDate":"2021-02-02","conditions":"Atrial Fibrillation (AF), Stroke","enrollment":1287},{"nctId":"NCT06517563","phase":"PHASE1","title":"Effects of VMX-C001 on the Anticoagulant Effect of Different Forms of Heparin","status":"ACTIVE_NOT_RECRUITING","sponsor":"VarmX B.V.","startDate":"2024-08-14","conditions":"Coagulation Disorder","enrollment":16},{"nctId":"NCT06581965","phase":"PHASE4","title":"inDividual, Targeted thrombosIS Prophylaxis Versus the Standard 'One Size Fits All' Approach in Patients Undergoing Total hIp or Total kNee replaCemenT","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2024-11-11","conditions":"Venous Thromboembolism, Venous Thromboses, Pulmonary Embolism","enrollment":10078},{"nctId":"NCT06965998","phase":"PHASE2, PHASE3","title":"A Pilot Trial Comparing Full Dose Rivaroxaban to Prophylactic Dose Rivaroxaban in Patients With Superficial Vein Thrombosis in the Leg","status":"RECRUITING","sponsor":"Ottawa Hospital Research Institute","startDate":"2025-08-06","conditions":"SVT, Thrombosis, Superficial Vein Thrombosis","enrollment":50},{"nctId":"NCT05990894","phase":"","title":"Steroid for Treatment of Acute/Subacute Severe Cerebral Venous Thrombosis.","status":"COMPLETED","sponsor":"Xuanwu Hospital, Beijing","startDate":"2020-07-01","conditions":"Cerebral Venous Thrombosis","enrollment":170},{"nctId":"NCT04700826","phase":"PHASE4","title":"Preventing Stroke, Premature Death and Cognitive Decline in a Broader Community of Patients With Atrial Fibrillation","status":"RECRUITING","sponsor":"University of Birmingham","startDate":"2021-06-01","conditions":"Atrial Fibrillation","enrollment":3000},{"nctId":"NCT05794399","phase":"PHASE4","title":"Anticoagulation in Post MI LV Thrombus Trial in Nepal","status":"RECRUITING","sponsor":"Shahid Gangalal National Heart Centre","startDate":"2023-06-19","conditions":"Left Ventricular Thrombus, Myocardial Infarction","enrollment":196},{"nctId":"NCT05735639","phase":"PHASE4","title":"THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)","status":"RECRUITING","sponsor":"Imperial College London","startDate":"2024-01-22","conditions":"Venous Thromboembolism, Varicose Veins","enrollment":6660},{"nctId":"NCT05797376","phase":"PHASE4","title":"Effects of aSPIrin Versus Aspirin Plus Low-dose RIvaroxaban on Carotid aTherosclerotic Plaque Inflammation","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2021-08-24","conditions":"Atherosclerosis of Artery, Coronary Artery Disease, Peripheral Arterial Disease","enrollment":92},{"nctId":"NCT06108414","phase":"PHASE4","title":"Low-dose Versus Standard-dose Rivaroxaban in Elderly Patients With Atrial Fibrillation","status":"RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2024-09-01","conditions":"Atrial Fibrillation, Anticoagulant Adverse Reaction, Stroke","enrollment":4374},{"nctId":"NCT06476301","phase":"PHASE4","title":"Efficacy and Safety of Rivaroxaban in the Early Postoperative Period for Patients With Bioprosthetic Valves","status":"NOT_YET_RECRUITING","sponsor":"RenJi Hospital","startDate":"2024-08-01","conditions":"Anticoagulation","enrollment":250},{"nctId":"NCT02590783","phase":"NA","title":"Treatment of Pelvic Ring Fractures in the Elderly","status":"TERMINATED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2017-10-17","conditions":"Pelvic Pain","enrollment":88},{"nctId":"NCT04066764","phase":"PHASE3","title":"Rivaroxaban and Vitamin K Antagonists for the Anticoagulation for the Implantation of Vena Cava Filters","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-05-08","conditions":"Venous Thromboembolism","enrollment":200},{"nctId":"NCT04067505","phase":"PHASE3","title":"Rivaroxaban for the Prevention of Deep Vein Thrombosis in Patients With Left Iliac Vein Compression - The PLICTS Study","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-05-18","conditions":"May-Thurner Syndrome","enrollment":224},{"nctId":"NCT02164578","phase":"PHASE3","title":"Microvascular and Antiinflammatory Effects of Rivaroxaban Compared to Aspirin in Type-2 Diabetic Patients With Subclinical Inflammation and High Cardiovascular Risk","status":"COMPLETED","sponsor":"GWT-TUD GmbH","startDate":"2015-04","conditions":"Type 2 Diabetic Patients","enrollment":179},{"nctId":"NCT02744092","phase":"NA","title":"Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer","status":"COMPLETED","sponsor":"Alliance Foundation Trials, LLC.","startDate":"2016-12-13","conditions":"Cancer, Venous Thromboembolism, Deep Vein Thrombosis (DVT)","enrollment":811},{"nctId":"NCT04753372","phase":"","title":"Rivaroxaban Plus Aspirin in Patients With Chronic Coronary Syndrome and High Ischemic Risk","status":"COMPLETED","sponsor":"Maatschap Cardiologie Zwolle","startDate":"2020-12-21","conditions":"Coronary Artery Disease (CAD), Peripheral Arterial Disease (PAD)","enrollment":645},{"nctId":"NCT00839163","phase":"PHASE2","title":"Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Proximal Deep Vein Thrombosis(ODIXa-DVT)","status":"COMPLETED","sponsor":"Bayer","startDate":"2004-03","conditions":"Venous Thrombosis, Deep Vein Thrombosis","enrollment":613},{"nctId":"NCT05960721","phase":"NA","title":"Low-dose NOAC Versus GDMT After LAAO","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2023-07-06","conditions":"Atrial Fibrillation","enrollment":4220},{"nctId":"NCT05546957","phase":"NA","title":"Assess Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban in Healthy Adult Participants","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-01-05","conditions":"Healthy Volunteer","enrollment":60},{"nctId":"NCT04006288","phase":"PHASE4","title":"Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease","status":"COMPLETED","sponsor":"University of Florida","startDate":"2019-09-06","conditions":"Coronary Artery Disease","enrollment":90},{"nctId":"NCT04002011","phase":"PHASE2","title":"DOAC Versus VKA After Cardiac Surgery","status":"WITHDRAWN","sponsor":"Laval University","startDate":"2022-03-09","conditions":"Anticoagulant-induced Bleeding","enrollment":""},{"nctId":"NCT05744804","phase":"NA","title":"Efficacy and Safety of Low Dose Rivaroxaban in Patients With Anterior Myocardial Infarction","status":"UNKNOWN","sponsor":"Sohag University","startDate":"2023-03-01","conditions":"Patient With Anterior Myocardial Infarction","enrollment":150},{"nctId":"NCT03310021","phase":"PHASE2","title":"A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian Subjects","status":"COMPLETED","sponsor":"Portola Pharmaceuticals","startDate":"2017-08-28","conditions":"Bleeding","enrollment":108},{"nctId":"NCT04569279","phase":"PHASE3","title":"Rivaroxaban vs. Warfarin in CVT Treatment","status":"COMPLETED","sponsor":"Damascus University","startDate":"2017-09-01","conditions":"Cerebral Vein Thrombosis","enrollment":71},{"nctId":"NCT05705076","phase":"NA","title":"Efficacy of Direct Oral Anticoagulants as a Prophylactic Anticoagulation of Catheter Induced Thrombosis","status":"UNKNOWN","sponsor":"Mansoura University","startDate":"2023-01-24","conditions":"Anticoagulants; Increased","enrollment":1100},{"nctId":"NCT04135677","phase":"PHASE4","title":"Clinical Outcomes Between Anticoagulation and DAPT Therapy in AF Patients Successfully Undergoing LAAO","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2022-11-11","conditions":"Left Atrial Appendage Thrombosis, Thrombi, Stroke","enrollment":826},{"nctId":"NCT05461807","phase":"","title":"An Observational Study Called H2H-OSCAR-US to Learn More About How Well Rivaroxaban Works and How Safe it is Compared to Apixaban Under Real World Conditions in People in the US With Cancer Who Have Problems Due to Formation of Blood Clots in the Veins (Venous Thromboembolism)","status":"COMPLETED","sponsor":"Bayer","startDate":"2022-07-14","conditions":"Treatment of Venous Thromboembolism in Cancer Patients, Venous Thromboembolism, Cancer","enrollment":2437},{"nctId":"NCT05545475","phase":"","title":"Safety of Anticoagulant Therapy After Tissue Glue for Gastric Varices","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2022-01-01","conditions":"Anticoagulants and Bleeding Disorders, Tissue Adhesion, Gastric Varices Bleeding","enrollment":100},{"nctId":"NCT04736901","phase":"","title":"Effect of Prophylactic and Therapeutic Anticoagulants in Egyptian Patients With COVID-19","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2020-12-01","conditions":"Covid19, Corona Virus Infection, Hypercoagulability","enrollment":90},{"nctId":"NCT03718429","phase":"PHASE4","title":"Pharmacodynamic Effects of Low-dose Rivaroxaban With Antiplatelet Therapies","status":"COMPLETED","sponsor":"University of Florida","startDate":"2019-01-14","conditions":"Coronary Artery Disease, Peripheral Arterial Disease, Atrial Fibrillation","enrollment":86},{"nctId":"NCT01999179","phase":"NA","title":"Post-thrombotic Syndrome & Predictors of Recurrence in Catheter-related Thrombosis","status":"COMPLETED","sponsor":"Medical College of Wisconsin","startDate":"2014-06","conditions":"Venous Thrombosis, Neoplasms","enrollment":27},{"nctId":"NCT04444804","phase":"","title":"Study to Compare the Effectiveness of Rivaroxaban (Xarelto) Versus Low-molecular-weight Heparin (LMWH) and Phenprocoumon for the Treatment and Secondary Prevention of Venous Thromboembolism in Routine Clinical Practice in Germany","status":"COMPLETED","sponsor":"Bayer","startDate":"2020-07-31","conditions":"Venous Thromboembolism","enrollment":22153},{"nctId":"NCT05210725","phase":"PHASE4","title":"Trained Immunity by Dual-pathway Inhibition in Coronary Artery Disease","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2022-03-01","conditions":"Coronary Artery Disease","enrollment":20},{"nctId":"NCT05233124","phase":"PHASE2","title":"Antithrombotic Therapy in Acute Coronary Syndromes and Coronary Artery Ectasia","status":"UNKNOWN","sponsor":"Instituto Nacional de Cardiologia Ignacio Chavez","startDate":"2021-09-01","conditions":"Acute Coronary Syndrome, Coronary Artery Ectasia","enrollment":60},{"nctId":"NCT04218656","phase":"PHASE4","title":"DUAL Pathway Inhibition to Improve Endothelial Function in Peripheral Artery Disease","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2020-06-08","conditions":"Peripheral Artery Disease","enrollment":159},{"nctId":"NCT01947959","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Germany)","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-12-22","conditions":"Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation","enrollment":665533},{"nctId":"NCT02468102","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)","status":"COMPLETED","sponsor":"Bayer","startDate":"2015-06-15","conditions":"Acute Coronary Syndrome, Venous Thrombosis, Pulmonary Embolism","enrollment":99999},{"nctId":"NCT01947985","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (Netherlands)","status":"COMPLETED","sponsor":"Bayer","startDate":"2012-02-01","conditions":"Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation","enrollment":208958},{"nctId":"NCT01947998","phase":"","title":"Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)","status":"COMPLETED","sponsor":"Bayer","startDate":"2011-12-22","conditions":"Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation","enrollment":50299},{"nctId":"NCT04158973","phase":"NA","title":"CHIPs-VTE Study in Hospitalized Patients With Lung Cancer","status":"UNKNOWN","sponsor":"China-Japan Friendship Hospital","startDate":"2021-12-01","conditions":"Venous Thromboembolic Disease, Pulmonary Embolism, Deep Venous Thrombosis","enrollment":3200},{"nctId":"NCT04935515","phase":"NA","title":"C Reactive Protein in Home Quarantined Coronavirus Disease 2019 (COVID -19) Patients.","status":"COMPLETED","sponsor":"Manimarane Arjunan, MD,DM (Cardiology)","startDate":"2021-04-15","conditions":"COVID -19","enrollment":25},{"nctId":"NCT04394377","phase":"PHASE4","title":"Full Anticoagulation Versus Prophylaxis in COVID-19: COALIZAO ACTION Trial","status":"COMPLETED","sponsor":"Brazilian Clinical Research Institute","startDate":"2020-06-21","conditions":"Coronavirus Infection","enrollment":615},{"nctId":"NCT02583191","phase":"PHASE3","title":"Rivaroxaban in the Treatment of Venous Thromboembolism (VTE) in Cancer Patients","status":"TERMINATED","sponsor":"AIO-Studien-gGmbH","startDate":"2016-03-23","conditions":"Venous Thromboembolism, Cancer","enrollment":246},{"nctId":"NCT04351724","phase":"PHASE2, PHASE3","title":"Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2020-04-16","conditions":"COVID-19","enrollment":500},{"nctId":"NCT02234843","phase":"PHASE3","title":"EINSTEIN Junior: Oral Rivaroxaban in Children With Venous Thrombosis","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-11-13","conditions":"Venous Thromboembolism","enrollment":500},{"nctId":"NCT03775746","phase":"PHASE4","title":"Can Very Low Dose Rivaroxaban in Addition to Dual Antiplatelet Therapy (DAPT) Improve Thrombotic Status in Acute Coronray Syndrome (ACS) ACS","status":"UNKNOWN","sponsor":"East and North Hertfordshire NHS Trust","startDate":"2019-01-08","conditions":"Acute Coronary Syndrome","enrollment":150},{"nctId":"NCT04192552","phase":"NA","title":"Perioperative Anticoagulant Use for Surgery Evaluation Study Part 2 Pilot","status":"UNKNOWN","sponsor":"McMaster University","startDate":"2020-01-09","conditions":"Atrial Fibrillation","enrollment":201},{"nctId":"NCT01727427","phase":"","title":"Prospective Study on the Treatment of Unsuspected Pulmonary Embolism in Cancer Patients","status":"COMPLETED","sponsor":"G. d'Annunzio University","startDate":"2012-11","conditions":"Unsuspected Pulmonary Embolism","enrollment":695},{"nctId":"NCT03804697","phase":"NA","title":"Selective Thromboembolism Prophylaxis After Arthroplasty","status":"COMPLETED","sponsor":"Guangdong Provincial People's Hospital","startDate":"2016-08-01","conditions":"Venous Thrombosis, Deep, Arthroplasty Complications","enrollment":197},{"nctId":"NCT03490994","phase":"PHASE4","title":"Rivaroxaban Once Daily Versus Dose-adjusted Vitamin K Antagonist on the Biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF)","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2018-04-10","conditions":"Acute Heart Failure","enrollment":150},{"nctId":"NCT02506985","phase":"PHASE4","title":"XENITH: Rivaroxaban for Pulmonary Embolism Managed With Catheter Directed Thrombolysis","status":"TERMINATED","sponsor":"Susan Smyth","startDate":"2015-07","conditions":"Pulmonary Embolism, Venous Thrombosis","enrollment":10},{"nctId":"NCT02921126","phase":"","title":"Real-World Evidence of Anticoagulation Treatment In Non-Valvular Atrial Fibrillation In Italy","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-04-30","conditions":"Anticoagulation","enrollment":9914},{"nctId":"NCT03481257","phase":"","title":"Comparison Between Ticagrelor Versus Very Low Dose Rivaroxaban With Clopidogrel","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2017-04-12","conditions":"Acute Coronary Syndrome, Acute Myocardial Infarction, Unstable Angina","enrollment":56},{"nctId":"NCT01684423","phase":"PHASE2","title":"Oral Rivaroxaban in Children With Venous Thrombosis","status":"COMPLETED","sponsor":"Bayer","startDate":"2013-02-19","conditions":"Venous Thrombosis","enrollment":64},{"nctId":"NCT01830543","phase":"PHASE3","title":"A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention","status":"COMPLETED","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2013-05-10","conditions":"Atrial Fibrillation, Percutaneous Coronary Intervention","enrollment":2124},{"nctId":"NCT01094886","phase":"PHASE3","title":"Switching Drug Therapy for the Prevention of Blood Clot Formation From Enoxaparin to Rivaroxaban After Orthopedic Surgery for Either Total Hip or Total Knee Replacement","status":"COMPLETED","sponsor":"Ortho-McNeil Janssen Scientific Affairs, LLC","startDate":"2010-03","conditions":"Arthritis, Osteoarthritis, Knee, Osteoarthritis, Hip","enrollment":56},{"nctId":"NCT01205932","phase":"PHASE3","title":"Dose-confirmatory Bridging Study in Total Hip Replacement","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-09","conditions":"Venous Thromboembolism","enrollment":402},{"nctId":"NCT01029743","phase":"","title":"Xarelto Regulatory Post-Marketing Surveillance","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-12","conditions":"Venous Thromboembolism","enrollment":3388},{"nctId":"NCT01206972","phase":"PHASE3","title":"Dose-confirmatory Bridging Study in Total Knee Replacement","status":"COMPLETED","sponsor":"Bayer","startDate":"2010-10","conditions":"Venous Thromboembolism","enrollment":302},{"nctId":"NCT02379663","phase":"PHASE4","title":"Prophylaxis of Deep Vein Thrombosis Following Total Hip Arthroplasty","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2012-01","conditions":"Osteoarthritis, Hip, Femur Head Necrosis, Femoral Neck Fractures","enrollment":639},{"nctId":"NCT00973323","phase":"PHASE2","title":"BAY59-7939 Japanese in Atrial Fibrillation (2nd)","status":"COMPLETED","sponsor":"Bayer","startDate":"2005-09","conditions":"Atrial Fibrillation","enrollment":100},{"nctId":"NCT00402467","phase":"PHASE2","title":"An Oral, Direct Factor Xa Inhibitor, BAY59-7939, for Prophylaxis Against Venous Thromboembolism After Total Knee Replacement: a Dose-Ranging Study","status":"COMPLETED","sponsor":"Bayer","startDate":"2004-02","conditions":"Venous Thromboembolism","enrollment":613},{"nctId":"NCT00839826","phase":"PHASE2","title":"ODiXahip - a Phase IIa Dose Escalating Proof of Principle Trial","status":"COMPLETED","sponsor":"Bayer","startDate":"2002-12","conditions":"Thromboembolism, Prevention","enrollment":641},{"nctId":"NCT00396786","phase":"PHASE2","title":"Dose-ranging Study of Once-daily Regimen of BAY 59-7939 in the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement","status":"COMPLETED","sponsor":"Bayer","startDate":"2004-11","conditions":"Venous Thromboembolism","enrollment":877},{"nctId":"NCT00329628","phase":"PHASE3","title":"Rivaroxaban (10mg) Given Once Daily in Patients Undergoing Total Hip Replacement Compared to Enoxaparin","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-02","conditions":"Venous Thromboembolism","enrollment":4541},{"nctId":"NCT00395772","phase":"PHASE2","title":"Once-daily Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Deep-vein Thrombosis","status":"COMPLETED","sponsor":"Bayer","startDate":"2004-12","conditions":"Venous Thromboembolism","enrollment":543},{"nctId":"NCT00361894","phase":"PHASE3","title":"Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE). A Study of BAY 59-7939 in the Prevention of VTE in Subjects Undergoing Elective Total Knee Replacement.","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-02","conditions":"Prevention, Venous Thromboembolism","enrollment":2531},{"nctId":"NCT00398905","phase":"PHASE2","title":"Dose-Ranging Study of BAY 59-7939 on the Prevention of VTE in Patients Undergoing Elective Total Hip Replacement","status":"COMPLETED","sponsor":"Bayer","startDate":"2004-01","conditions":"Venous Thromboembolism","enrollment":726}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":252,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"low-dose rivaroxaban","genericName":"low-dose rivaroxaban","companyName":"China National Center for Cardiovascular Diseases","companyId":"china-national-center-for-cardiovascular-diseases","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rivaroxaban is used to treat conditions such as Pelvic Pain, Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation, and Acute Coronary Syndrome. It is a medication that works by inhibiting Factor Xa, a key component in the blood clotting process.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}